Ligustrazine improves atherosclerosis in rat via attenuation of oxidative stress

References

• Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. (1986). Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA, 256, 2835–2838.
   PubMed Web of Science ®Google Scholar
• Chang Y, Hsiao G, Chen SH, Chen YC, Lin JH, Lin KH, Chou DS, Sheu JR. (2007). Tetramethylpyrazine suppresses HIF-1alpha, TNF-alpha, and activated caspase-3 expression in middle cerebral artery occlusion-induced brain ischemia in rats. Acta Pharmacol Sin, 28, 327–333.
   PubMed Web of Science ®Google Scholar
• Clarke LA, Shah V, Arrigoni F, Eleftheriou D, Hong Y, Halcox J, Klein N, Brogan PA. (2008). Quantitative detection of circulating endothelial cells in vasculitis: Comparison of flow cytometry and immunomagnetic bead extraction. J Thromb Haemost, 6, 1025–1032.
   PubMed Web of Science ®Google Scholar
• Duprez DA, Cohn JN. (2007). Arterial stiffness as a risk factor for coronary atherosclerosis. Curr Atheroscler Rep, 9, 139–144.
   PubMedGoogle Scholar
• Goldstein JL, Hazzard WR, Schrott HG, Bierman EL, Motulsky AG. (1973). Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. J Clin Invest, 52, 1533–1543.
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA. (1989). High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation, 79, 8–15.
   PubMed Web of Science ®Google Scholar
• Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. (1977). High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med, 62, 707–714.
   PubMed Web of Science ®Google Scholar
• Hansson GK. (2009). Inflammatory mechanisms in atherosclerosis. J Thromb Haemost, 7 (Suppl 1), 328–331.
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Cook WS, Qi C, Yeldandi AV, Reddy JK, Rao MS. (2000). Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J Biol Chem, 275, 28918–28928.
   PubMed Web of Science ®Google Scholar
• Holvoet P, Lee DH, Steffes M, Gross M, Jacobs DR Jr. (2008). Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA, 299, 2287–2293.
   PubMed Web of Science ®Google Scholar
• Hsiai T, Berliner JA. (2007). Oxidative stress as a regulator of murine atherosclerosis. Curr Drug Targets, 8, 1222–1229.
   PubMed Web of Science ®Google Scholar
• Illingworth DR, Bacon S. (1987). Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia. Am J Cardiol, 60, 33G–42G.
   Web of Science ®Google Scholar
• Ishigaki Y, Oka Y, Katagiri H. (2009). Circulating oxidized LDL: A biomarker and a pathogenic factor. Curr Opin Lipidol, 20, 363–369.
   PubMed Web of Science ®Google Scholar
• Kim JW, Kang KW, Oh GT, Song J, Kim ND, Pak YK. (2002). Induction of hepatic inducible nitric oxide synthase by cholesterol in vivo and in vitro. Exp Mol Med, 34, 137–144.
   PubMed Web of Science ®Google Scholar
• Kitagawa S, Yamaguchi Y, Kunitomo M, Imaizumi N, Fujiwara M. (1993). Altered vasoconstrictor responsiveness in vitamin D-induced arteriosclerotic rat aortas. Jpn J Pharmacol, 61, 283–289.
   PubMedGoogle Scholar
• Kobayashi S, Inoue N, Azumi H, Seno T, Hirata K, Kawashima S, Hayashi Y, Itoh H, Yokozaki H, Yokoyama M. (2002). Expressional changes of the vascular antioxidant system in atherosclerotic coronary arteries. J Atheroscler Thromb, 9, 184–190.
   PubMedGoogle Scholar
• Li YJ, Li YJ, Wu JX, Yu XJ, Yan YF. (1994). Protective effect of tetramethylpyrazine against damages of aortic endothelial cells elicited by low-density lipoproteins. Zhongguo Yao Li Xue Bao, 15, 407–410.
   PubMed Web of Science ®Google Scholar
• Lizardi-Cervera J, Aguilar-Zapata D. (2009). Nonalcoholic fatty liver disease and its association with cardiovascular disease. Ann Hepatol, 8 (Suppl 1), S40–S43.
   Google Scholar
• Makin AJ, Chung NA, Silverman SH, Lip GY. (2003). Thrombogenesis and endothelial damage/dysfunction in peripheral artery disease. Relationship to ethnicity and disease severity. Thromb Res, 111, 221–226.
   PubMed Web of Science ®Google Scholar
• Muniyappa R, Montagnani M, Koh KK, Quon MJ. (2007). Cardiovascular actions of insulin. Endocr Rev, 28, 463–491.
   PubMed Web of Science ®Google Scholar
• Peng W, Hucks D, Priest RM, Kan YM, Ward JP. (1996). Ligustrazine-induced endothelium-dependent relaxation in pulmonary arteries via an NO-mediated and exogenous l-arginine-dependent mechanism. Br J Pharmacol, 119, 1063–1071.
   PubMed Web of Science ®Google Scholar
• Puddu GM, Cravero E, Arnone G, Muscari A, Puddu P. (2005). Molecular aspects of atherogenesis: New insights and unsolved questions. J Biomed Sci, 12, 839–853.
   PubMed Web of Science ®Google Scholar
• Roberts CK, Barnard RJ, Sindhu RK, Jurczak M, Ehdaie A, Vaziri ND. (2006). Oxidative stress and dysregulation of NAD(P)H oxidase and antioxidant enzymes in diet-induced metabolic syndrome. Metab Clin Exp, 55, 928–934.
   PubMed Web of Science ®Google Scholar
• Seyama Y, Wachi H. (2004). Atherosclerosis and matrix dystrophy. J Atheroscler Thromb, 11, 236–245.
   PubMedGoogle Scholar
• Singh U, Jialal I. (2006). Oxidative stress and atherosclerosis. Pathophysiology, 13, 129–142.
   PubMedGoogle Scholar
• Soccio M, Toniato E, Evangelista V, Carluccio M, De Caterina R. (2005). Oxidative stress and cardiovascular risk: The role of vascular NAD(P)H oxidase and its genetic variants. Eur J Clin Invest, 35, 305–314.
   PubMed Web of Science ®Google Scholar
• Song S, Zhang Y, Ma K, Jackson-Hayes L, Lavrentyev EN, Cook GA, Elam MB, Park EA. (2004). Peroxisomal proliferator activated receptor gamma coactivator (PGC-1alpha) stimulates carnitine palmitoyltransferase I (CPT-Ialpha) through the first intron. Biochim Biophys Acta, 1679, 164–173.
   PubMedGoogle Scholar
• St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jäger S, Handschin C, Zheng K, Lin J, Yang W, Simon DK, Bachoo R, Spiegelman BM. (2006). Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell, 127, 397–408.
   PubMed Web of Science ®Google Scholar
• Sun Y, Jiang J, Zhang Z, Yu P, Wang L, Xu C, Liu W, Wang Y. (2008). Antioxidative and thrombolytic TMP nitrone for treatment of ischemic stroke. Bioorg Med Chem, 16, 8868–8874.
   PubMed Web of Science ®Google Scholar
• Sutter MC, Wang YX. (1993). Recent cardiovascular drugs from Chinese medicinal plants. Cardiovasc Res, 27, 1891–1901.
   PubMed Web of Science ®Google Scholar
• Victor VM, Rocha M, Solá E, Bañuls C, Garcia-Malpartida K, Hernández-Mijares A. (2009). Oxidative stress, endothelial dysfunction and atherosclerosis. Curr Pharm Des, 15, 2988–3002.
   PubMed Web of Science ®Google Scholar
• Wong KL, Chan P, Huang WC, Yang TL, Liu IM, Lai TY, Tsai CC, Cheng JT. (2003). Effect of tetramethylpyrazine on potassium channels to lower calcium concentration in cultured aortic smooth muscle cells. Clin Exp Pharmacol Physiol, 30, 793–798.
   PubMed Web of Science ®Google Scholar
• Woo KS, Chook P, Raitakari OT, McQuillan B, Feng JZ, Celermajer DS. (1999). Westernization of Chinese adults and increased subclinical atherosclerosis. Arterioscler Thromb Vasc Biol, 19, 2487–2493.
   PubMed Web of Science ®Google Scholar
• Wu GX, Wu JC, Ma HT, Ruan CG. (1992). Inhibitory effects of tetramethylpyrazine on platelets during cardiopulmonary bypass and arterial thrombus formation in dogs. Zhongguo Yao Li Xue Bao, 13, 330–333.
   PubMed Web of Science ®Google Scholar
• Zhang ZH, Yu SZ, Wang ZT, Zhao BL, Hou JW, Yang FJ, Xin WJ. (1994). Scavenging effects of tetramethylpyrazine on active oxygen free radicals. Zhongguo Yao Li Xue Bao, 15, 229–231.
   PubMed Web of Science ®Google Scholar